Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma

Robb, Victoria A., Karbowniczek, Magdalena, Klein-Szanto, Andres J., Henske, Elizabeth P. · 2007 · Journal of Urology

Abstract

PURPOSE: We determined the frequency of mTOR/p70S6 kinase signaling pathway activation in clear cell renal cell carcinoma. MATERIALS AND METHODS: Phospho-S6 (Ser235/236) and phospho-mTOR (Ser2448) staining was performed on renal tumor tissue microarrays containing 29 clear cell renal cell carcinomas. Mutational analysis of Rheb and RhebL1 was performed on DNA from phospho-mTOR/phospho-S6 positive clear cell renal cell carcinoma. The 3 clear cell renal cell carcinoma derived cell lines A498, 786-O and Caki1 were also assessed for mTOR activation and the effect of the mTOR inhibitor rapamycin (Biomol) on proliferation. RESULTS: Moderate or strong phospho-S6 immunoreactivity was found in 17 of 29 clear cell carcinomas (59%), of which 14 were also moderately/strongly positive for phospho-mTOR (Ser2448). We hypothesized that this activation of the mTOR signaling pathway in clear cell renal cell carcinoma could reflect mutational activation of Rheb or RhebL1, which are Ras family members that directly activate mTOR. However, no mutations in exons 3 and 4 (homologous sites of Ras activating mutations) in Rheb or RhebL1 were identified. Two of 3 renal clear cell carcinoma derived cell lines also showed inappropriate S6 hyperphosphorylation. Treatment of all 3 cell lines with rapamycin significantly decreased S6 phosphorylation and proliferation. CONCLUSIONS: The mTOR/p70S6 kinase signaling pathway is activated in most clear cell renal cell carcinomas. Moreover, the growth of renal clear cell carcinoma derived cell lines is inhibited by rapamycin. This is especially significant in light of new agents such as CCI-779, an ester of rapamycin and inhibitor of mTOR, which has shown promise in the treatment of renal carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.juro.2006.08.076

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 165

Metadata

Authors
Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J., & Henske, E. P.
Venue
Journal of Urology
Published
2007-01
Volume
177
Issue
1
Pages
346-352
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W1994512948
Cited by
165
References
5
FWCI
4.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma. https://app.cochat.ai/papers/10.1016/j.juro.2006.08.076
The paper
Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J., & Henske, E. P. (2007). Activation of the mTOR Signaling Pathway in Renal Clear Cell Carcinoma. Journal of Urology. https://doi.org/10.1016/j.juro.2006.08.076

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.